Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome

Int J Immunopathol Pharmacol. 2005 Jan-Mar;18(1):59-64. doi: 10.1177/039463200501800107.

Abstract

Squamous cell carcinoma (SCC) of the lip is a relatively common malignancy of the head and neck region. Tumour thickness, grading and perineural invasion are significant prognostic indicators. However, there is still the need of new reliable biological markers able to predict the prognosis of the single cases with an unfavourable biological behaviour unpredictable by the classic clinical-pathological parameters. 32 cases of (SCC) of the lower lip were analysed for their clincopathologic features, and immunohistochemical expression of Fas/FasL in neoplastic cells and in inflammatory infiltrate. Moreover the density and phenotype of tumour-infiltrating lymphocytes (TIL) were analysed. The results were related with the follow-up of the patients ranging from 2 to 6 years. The cases with over-expression of Fas/FasL in neoplastic cells and Fas+ in T cells preferentially showed a more aggressive clinical behaviour (P<0.01). Moreover we found an alteration of the normal expression of CD4 and CD8 lymphocyte types in ten cases. This data suggest that the Fas/FasL pathway is involved in the close relation between neoplastic cells and T cells and so in the biological behaviour of these tumours.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Aging / physiology
  • CD4 Antigens / immunology
  • CD8 Antigens / immunology
  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / immunology
  • Carcinoma, Squamous Cell / pathology*
  • Fas Ligand Protein
  • Female
  • Humans
  • Image Processing, Computer-Assisted
  • Immune Tolerance / physiology
  • Immunohistochemistry
  • Lip Neoplasms / genetics*
  • Lip Neoplasms / immunology
  • Lip Neoplasms / pathology*
  • Lymphatic Metastasis / pathology
  • Lymphocytes / pathology*
  • Male
  • Membrane Glycoproteins / genetics*
  • Middle Aged
  • Sex Characteristics
  • Treatment Outcome

Substances

  • CD4 Antigens
  • CD8 Antigens
  • FASLG protein, human
  • Fas Ligand Protein
  • Membrane Glycoproteins